\chapter{Materials and Methods}

\section{Patient identification}


% The cohort for analysis was identified from an institutional database of NSCLC patients st st undergoing routine clinical tumor genotyping between January 1 , 2002 and January 1 , 2014.
% Patients were eligible if they consented to allow their clinical information to be used in retrospective research studies on an institutional review board (IRB)-approved protocol (Dana- Farber/Harvard Cancer Center protocol #02-180), or if they were deceased and data was made available on an IRB-approved waiver of consent. The database was queried for information on age, sex, race, smoking status, date of diagnosis, histology, stage, and date of death. Race was included given known associations between tumor genetics and patient race.


\section{Laboratory Procedures}
